FDA Needs To Revamp Benefit-Risk Analysis, Drugmakers Say
The U.S. Food and Drug Administration's new process for analyzing a drug's benefits and risks needs to be drastically expanded, patient groups and drug companies have argued, saying if the agency...To view the full article, register now.
Already a subscriber? Click here to view full article